Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 219.00p on 06-02-2026 at 19:35:12
Change -4.00p -1.83%
Buy 219.00p
Sell 209.00p
Last Trade: Sell 500.00 at 211.00p
Day's Volume: 5,063
Last Close: 214.00p
Open: 207.00p
ISIN: KYG4672N1198
Day's Range 207.00p - 219.00p
52wk Range: 187.50p - 292.00p
Market Capitalisation: £1.88b
VWAP: 210.25044p
Shares in Issue: 859.52m

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 500 211.00p Ordinary
16:28:58 - 06-Feb-26
Buy* 332 219.00p Automatic Execution
16:27:27 - 06-Feb-26
Buy* 121 218.00p Automatic Execution
16:17:31 - 06-Feb-26
Sell* 121 213.00p Automatic Execution
16:09:19 - 06-Feb-26
Buy* 90 218.00p Automatic Execution
16:09:19 - 06-Feb-26
Unknown* 0 218.00p SI Trade
14:17:52 - 06-Feb-26
Sell* 1,713 209.00p Ordinary
11:37:32 - 06-Feb-26
Sell* 2,000 209.00p Ordinary
10:55:31 - 06-Feb-26
Unknown* 37 207.00p OTC Trade
08:54:09 - 06-Feb-26
Unknown* 29 207.00p OTC Trade
08:54:09 - 06-Feb-26
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
6th Feb 2026 (Fri) 207.00 219.00 207.00 214.00 5,063
5th Feb 2026 (Thu) 218.00 218.00 218.00 218.00 28,629
4th Feb 2026 (Wed) 219.00 219.00 219.00 219.00 3,324
3rd Feb 2026 (Tue) 206.00 217.00 204.00 217.00 54,828
2nd Feb 2026 (Mon) 213.00 216.00 212.00 216.00 53,065
30th Jan 2026 (Fri) 216.00 220.00 216.00 220.00 8,140
29th Jan 2026 (Thu) 222.00 222.00 222.00 219.00 12,427
28th Jan 2026 (Wed) 222.00 222.00 220.00 220.00 30,920
27th Jan 2026 (Tue) 224.00 224.00 221.00 221.00 68,719
26th Jan 2026 (Mon) 232.00 232.00 232.00 226.50 26,453
23rd Jan 2026 (Fri) 232.00 233.00 225.00 225.00 298,129
22nd Jan 2026 (Thu) 226.00 230.00 225.00 226.00 103,635
21st Jan 2026 (Wed) 226.00 228.00 223.00 225.00 88,505
20th Jan 2026 (Tue) 239.00 239.00 225.00 225.00 2,357
19th Jan 2026 (Mon) 239.00 239.00 239.00 232.50 1,598
16th Jan 2026 (Fri) 231.00 239.00 230.00 239.00 141,476
15th Jan 2026 (Thu) 225.00 228.00 220.00 226.00 42,581
14th Jan 2026 (Wed) 220.00 225.00 210.00 210.00 8,157
13th Jan 2026 (Tue) 223.00 223.00 219.00 221.00 19,690
12th Jan 2026 (Mon) 225.00 225.00 211.00 225.00 25,444
9th Jan 2026 (Fri) 218.00 218.00 215.00 217.00 9,470
8th Jan 2026 (Thu) 214.00 218.00 214.00 218.00 8,809
7th Jan 2026 (Wed) 210.00 218.00 210.00 214.00 18,547
See more Hutchmed price history

Hutchmed (HCM) Regulatory News

Date Source Headline
6th Feb 2026 8:30 am RNS HUTCHMED to Announce 2025 Final Results
14th Jan 2026 7:00 am RNS-R Publication of Phase III Results in The Lancet
7th Jan 2026 7:00 am RNS-R Positive Topline Results of Phase III Trial
5th Jan 2026 7:00 am RNS-R Surufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 2025 7:00 am RNS Total Voting Rights
31st Dec 2025 7:00 am RNS Total Voting Rights
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 2025 8:30 am RNS Blocklisting Six Monthly Return
29th Dec 2025 8:30 am RNS-R NDA Acceptance in China for Fanregratinib
See more Hutchmed regulatory news

Hutchmed (HCM) Share News

Hutchmed China hails lung cancer trial results published in Lancet

14th Jan 2026 12:06

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More

Hutchmed China hails sovleplenib results for form of anaemia in China

7th Jan 2026 11:41

(Alliance News) - Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. Read More

Hutchmed China kicks off phase three stage of pancreatic cancer trial

5th Jan 2026 10:45

(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More

Hutchmed savolitinib NDA for gastric cancer accepted in China

30th Dec 2025 11:21

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More

Hutchmed drug gains China priority review for bile duct cancer

29th Dec 2025 10:51

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status. Read More

See more Hutchmed news
FTSE 100 Latest
Value10,369.75
Change60.53

Login to your account

Forgot Password?

Not Registered